Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Bisphosphonates are increasingly recognized for their anti-neoplastic properties, which are the result of their action on the mevalonate pathway. Our primary aim was to investigate the association between bisphosphonate use and survival in patients with pancreatic cancer. Since statins also act on the mevalonate pathway, we also investigated the effect of the combined use of bisphosphonates and statins on survival. Methods: The Surveillance, Epidemiology, and End Results registry (SEER)-Medicare linked database was used to identify patients with pancreatic ductal adenocarcinoma (PDAC) between 2007 and 2015. Kaplan-Meier models were used to examine the association between survival with bisphosphonate use alone and in combination with statins within 1 year prior to the diagnosis of PDAC. Propensity score matching analysis and Cox-proportional hazard models were used to determine the association between overall survival with bisphosphonate use alone and combined with statins, after adjusting for relevant confounders, such as the Charlson comorbidity index score, stage, treatment, sociodemographic characteristics, and propensity score. Results: In total, 13,639 patients with PDAC were identified, and 1,203 (8.82%) used bisphosphonates. There was no difference in the mean survival duration between bisphosphonate users (7.27 months) and nonusers (7.25 months, p=0.61). After adjustment for confounders, bisphosphonate use was still not associated with improved survival (hazard ratio, 1.00; 95% confidence interval, 0.93 to 1.08; p=0.96). Combined bisphosphonate and statin use was also not associated with improved survival (hazard ratio, 0.97; 95% confidence interval, 0.87 to 1.07; p=0.48) after adjustment for confounders. Conclusions: Our findings suggest that the use of bisphosphonates, whether alone or in combination with statins, does not confer a survival advantage in patients with PDAC.
Abstract
Background/Aims: Bisphosphonates are increasingly recognized for their anti-neoplastic properties, which are the result of their action on the mevalonate pathway. Our primary aim was to investigate the association between bisphosphonate use and survival in patients with pancreatic cancer. Since statins also act on the mevalonate pathway, we also investigated the effect of the combined use of bisphosphonates and statins on survival. Methods: The Surveillance, Epidemiology, and End Results registry (SEER)-Medicare linked database was used to identify patients with pancreatic ductal adenocarcinoma (PDAC) between 2007 and 2015. Kaplan-Meier models were used to examine the association between survival with bisphosphonate use alone and in combination with statins within 1 year prior to the diagnosis of PDAC. Propensity score matching analysis and Cox-proportional hazard models were used to determine the association between overall survival with bisphosphonate use alone and combined with statins, after adjusting for relevant confounders, such as the Charlson comorbidity index score, stage, treatment, sociodemographic characteristics, and propensity score. Results: In total, 13,639 patients with PDAC were identified, and 1,203 (8.82%) used bisphosphonates. There was no difference in the mean survival duration between bisphosphonate users (7.27 months) and nonusers (7.25 months, p=0.61). After adjustment for confounders, bisphosphonate use was still not associated with improved survival (hazard ratio, 1.00; 95% confidence interval, 0.93 to 1.08; p=0.96). Combined bisphosphonate and statin use was also not associated with improved survival (hazard ratio, 0.97; 95% confidence interval, 0.87 to 1.07; p=0.48) after adjustment for confounders. Conclusions: Our findings suggest that the use of bisphosphonates, whether alone or in combination with statins, does not confer a survival advantage in patients with PDAC.
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
- Vincent A, "Pancreatic cancer", Lancet, 378, pp.607~620 (2011)
- Sunil Amin, "The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer", Gut and Liver, 10(5), pp.665~671 (2016), 거트앤리버 소화기연관학회협의회
- Gnant M, "Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature", Cancer Treat Rev, 38, pp.407~415 (2012)
- Asahi H, "Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells", Int J Urol, 13, pp.593~600 (2006)
- Daubiné F, "Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis", J Natl Cancer Inst, 99, pp.322~330 (2007)
- Tassone P, "Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro", Br J Cancer, 88, pp.1971~1978 (2003)
- Singh S, "Bisphosphonates are associated with reduced risk of colorectal cancer : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.232~239 (2013)
- Ou YJ, "Bisphosphonate use and the risk of breast cancer : a meta-analysis of observational studies", Pharmacoepidemiol Drug Saf, 26, pp.1286~1295 (2017)
- "Breast Cancer Res", 2006, R13~
- Gnant M, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer : 5-year followup of the ABCSG-12 bone-mineral density substudy", Lancet Oncol, 9, pp.840~849 (2008)
- Cardwell CR, "Exposure to oral bisphosphonates and risk of cancer", Int J Cancer, 131, pp.E717~ (2012)
- Vinogradova Y, "Exposure to bisphosphonates and risk of common non-gastrointestinal cancers : series of nested case-control studies using two primary-care databases", Br J Cancer, 109, pp.795~806 (2013)
- Thurnher M, "Novel aspects of mevalonate pathway inhibitors as antitumor agents", Clin Cancer Res, 18, pp.3524~3531 (2012)
- Biankin AV, "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes", Nature, 491, pp.399~405 (2012)
- Vallianou NG, "Statins and cancer", Anticancer Agents Med Chem, 14, pp.706~712 (2014)
- Wang D, "Statin use shows increased overall survival in patients diagnosed with pancreatic cancer : a meta-analysis", Pancreas, 48, pp.e22~ (2019)
- Elsayed M, "Synergistic antiproliferative effects of zoledronic acid and fluvastatin on human pancreatic cancer cell lines : an in vitro study", Biol Pharm Bull, 39, pp.1238~1246 (2016)
- Kawashiri T, "Antitumor activities of 3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA)reductase inhibitors and bisphosphonates in pancreatic cell lines which show poor responses to gemcitabine", Biol Pharm Bull, 43, pp.49~52 (2020)
- El-Refai SM, "Epidemiologic analysis along the mevalonate pathway reveals improved cancer survival in patients who receive statins alone and in combination with bisphosphonates", JCO Clin Cancer Inform, 1, pp.1~12 (2017)
- Deyo RA, "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases", J Clin Epidemiol, 45, pp.613~619 (1992)
- Amin S, "Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes : a propensity score analysis", Am J Gastroenterol, 111, pp.1350~1357 (2016)
- Takiguchi S, "The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model", Oncol Rep, 28, pp.111~116 (2012)
- Hiroshima Y, "The tumoreducated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid", PLoS One, 9, pp.e103382~ (2014)
- Drake MT, "Bisphosphonates : mechanism of action and role in clinical practice", Mayo Clin Proc, 83, pp.1032~1045 (2008)
- Borad MJ, "Skeletal metastases in pancreatic cancer : a retrospective study and review of the literature", Yale J Biol Med, 82, pp.1~6 (2009)
- Peila R, "Association of sex hormones with risk of cancers of the pancreas, kidney, and brain in the UK Biobank cohort study", Cancer Epidemiol Biomarkers Prev, 29, pp.1832~1836 (2020)
- Abdel-Rahman O, "Statin treatment and outcomes of metastatic pancreatic cancer : a pooled analysis of two phase III studies", Clin Transl Oncol, 21, pp.810~816 (2019)
- Gbelcová H, "Differences in antitumor effects of various statins on human pancreatic cancer", Int J Cancer, 122, pp.1214~1221 (2008)
- Dai C, "Statin use and the overall survival in patients diagnosed with pancreatic cancer", Pancreas, 49, pp.e19~ (2020)